BMY Bristol Myers Squibb

XNYS Sideways Alert

Health Care

· How we analyze

About the company

Bristol Myers Squibb is a pharmaceutical company from New Jersey. Its focus areas are cancer drugs such as Opdivo, blood thinners (Eliquis, together with Pfizer), immunology and cardiovascular disease. The acquisition of Karuna added a schizophrenia treatment. As of Oct 11, 2026

Fact sheet (from the annual report) Pharmaceutical manufacturers · Princeton, USA

The company researches, develops, manufactures and markets medicines in a single segment. Its therapeutic areas are oncology, hematology, immunology, cardiovascular disease and neuroscience. Its products include Opdivo and Yervoy for several types of cancer, the anticoagulant Eliquis and Revlimid for multiple myeloma. Customers are mainly wholesalers, distributors and specialty pharmacies, and to a lesser extent also retailers, hospitals and government agencies. In the US market, Revlimid and Pomalyst are distributed mainly through contracted pharmacies with mandatory risk programs. Manufacturing sites include Puerto Rico, among others.

Automatically summarized from SEC annual report (10-K, filed Feb 11, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

What the methods say about Bristol Myers Squibb

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today +0.2%
  • 7 days +4.7%
  • 30 days −2.0%
  • 1 year +40.6%
Day range (last trading day)
−0.8%Price at 53% of the range+0.7%
52-week range
−31.0%Price at 73% of the range+11.4%
Distance from the all-time high
−24.3%

Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:BMY

Save zone

With a free account: save the buy zone shown for yourself (stop and targets from Watcher). It stays visible even if the zone changes later. Log in · Sign up

Fundamental analysis

Bristol Myers Squibb · Sector Health Care · amounts in USD

Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 11, 2026.

In short

  • Light yellow: Revenue grew over 5 years (+2.5% per year), more slowly than the sector median.
  • Light green: Net margin 14.6%, above the sector median (12.9%).
  • Light red: Debt much higher than usual in the sector.
  • Light red: Profit in 8 of 10 fiscal years.
  • Light yellow: High payout ratio (72% of earnings).

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 19.4B USD · Net income 4.5B USD · Net margin 22.9%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 20.8B USD · Net income 1.0B USD · Net margin 4.8%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 22.6B USD · Net income 4.9B USD · Net margin 21.8%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 26.1B USD · Net income 3.4B USD · Net margin 13.2%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 42.5B USD · Net income −9.0B USD · Net margin −21.2%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 46.4B USD · Net income 7.0B USD · Net margin 15.1%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 46.2B USD · Net income 6.3B USD · Net margin 13.7%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 45.0B USD · Net income 8.0B USD · Net margin 17.8%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 48.3B USD · Net income −8.9B USD · Net margin −18.5%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 48.2B USD · Net income 7.1B USD · Net margin 14.6%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 48.2B USD · Net income 7.1B USD · Net margin 14.6%

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+2.5% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 2.5% per year on average, but more slowly than the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light gray: not computable

– per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: not computable (loss in the first or last year)

What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

14.6% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 14.64 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was −21.2%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light red: much higher

1.92 latest balance sheet

Sector Health Care: median 0.66 (40 symbols)

What does this mean? For every 1 USD of equity there is 1.92 USD of financial debt – more than twice as much as the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light yellow: high

72% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.72 USD went to shareholders as a dividend. Little buffer remains for weaker years. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light red: 2 loss years

8 of 10 fiscal years with a profit

What does this mean? In 8 of the last 10 fiscal years the bottom line showed a profit. 2 years ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
48.2B USD
Revenue vs. prior year
−0.2%
Net income (FY)
7.1B USD
Net income vs. prior year
–
EPS (FY)
3.46 USD
13F funds with a position
0 of 9
Funds vs. prior quarter
−1
Shares held vs. prior quarter
−100.0%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 11, 2026 · Balance sheet Jun 30, 2026 (filed Jul 30, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 48.2B7.1B 14.6% 3.46 2.49 72%
2024Dec 31, 2024 48.3B−8.9B −18.5% −4.41 2.42 –
2023Dec 31, 2023 45.0B8.0B 17.8% 3.86 2.31 60%
2022Dec 31, 2022 46.2B6.3B 13.7% 2.95 2.19 74%
2021Dec 31, 2021 46.4B7.0B 15.1% 3.12 2.01 64%
2020Dec 31, 2020 42.5B−9.0B −21.2% −3.99 1.84 –
2019Dec 31, 2019 26.1B3.4B 13.2% 2.01 1.68 84%
2018Dec 31, 2018 22.6B4.9B 21.8% 3.01 1.61 53%
2017Dec 31, 2017 20.8B1.0B 4.8% 0.61 1.57 257%
2016Dec 31, 2016 19.4B4.5B 22.9% 2.65 1.53 58%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 30, 2026 13.0B3.3B 25.6% 1.62 0.63 39%
Q1/26Mar 31, 2026 11.5B2.7B 23.3% 1.31 0.63 48%
Q4/25*Dec 31, 2025 12.5B1.1B 8.7% – – –
Q3/25Sep 30, 2025 12.2B2.2B 18.0% 1.08 0.62 57%
Q2/25Jun 30, 2025 12.3B1.3B 10.7% 0.64 0.62 97%
Q1/25Mar 31, 2025 11.2B2.5B 21.9% 1.20 0.62 52%
Q4/24*Dec 31, 2024 12.3B72.0M 0.6% – – –
Q3/24Sep 30, 2024 11.9B1.2B 10.2% 0.60 0.60 100%
Q2/24Jun 30, 2024 12.2B1.7B 13.8% 0.83 0.60 72%
Q1/24Mar 31, 2024 11.9B−11.9B −100.4% −5.89 0.60 –
Q4/23*Dec 31, 2023 11.5B1.8B 15.4% – – –
Q3/23Sep 30, 2023 11.0B1.9B 17.6% 0.93 0.57 61%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $437.2K2 people −$437.2K
6 months $00 people $437.2K2 people −$437.2K
12 months $00 people $2.3M3 people −$2.3M

Latest transactions

  • Sep 9, 2026 Massacesi Cristian Officer Open-market sale 6,249 shares · $403.5K · SEC
  • Aug 25, 2026 Holzer Phil M Officer Open-market sale 500 shares · $33.8K · SEC
  • Apr 1, 2026 Elkins David V Chief financial officer (CFO) Open-market sale 4,481 shares · $278.0K · SEC
  • Apr 1, 2026 Elkins David V Chief financial officer (CFO) Open-market sale 25,519 shares · $1.6M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score -15

Price vs. EMA 50-15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+0
Highs and lows-20
Relative strength-15

Volatility and trend strength

ADX 14 (trend strength)17.6
Rel. strength 60 d−7.9%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on BMY yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: BMY

Alerts with a free account: we send you an email as soon as the price moves above or below your level, reaches the buy zone or the buy zone becomes invalid.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close